You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / CE

Case Challenges in Chronic Lymphocytic Leukemia

  • Authors: Matthew Lunning, DO, FACP
  • CME / CE Released: 8/31/2022
  • Valid for credit through: 8/31/2023
Start Activity

  • Credits Available

    Physicians - maximum of 0.50 AMA PRA Category 1 Credit(s)™

    Nurses - 0.50 ANCC Contact Hour(s) (0 contact hours are in the area of pharmacology)

    You Are Eligible For

    • Letter of Completion

Target Audience and Goal Statement

This activity is intended for the interprofessional leukemia clinical team, including oncologists, hematologists, clinical scientists, nurse practitioners, physician assistants, and nurses.

The goal of this activity is that learners will be better able to obtain practical strategies to personalize treatment and manage side effects for patients with treatment-naive or relapsed/refractory (R/R) CLL.

Upon completion of this activity, participants will:

  • Discuss the evidence supporting measurable residual disease (MRD) testing in CLL (knowledge)
  • Apply personalized therapy for patients with treatment-naive CLL (competence)
  • Explore sequencing therapy for patients with R/R CLL (competence)
  • Demonstrate their ability to work as part of an interprofessional team to manage side effects of CLL treatments (confidence)


Disclosures

As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance,  objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. Faculty (authors, presenters, speakers) are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or other options available when utilizing trade names to ensure impartiality.  

All faculty, planners, and others in a position to control continuing education content participating in a UNMC accredited activity are required to disclose all financial relationships with ineligible companies. As defined by the Standards for Integrity and Independence in Accredited Continuing Education, ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating relevant financial relationships in accredited continuing education. Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.  

This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.  

All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.

The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles:


Faculty

  • Matthew Lunning, DO, FACP

    Associate Professor
    Division of Oncology and Hematology
    Department of Internal Medicine
    University of Nebraska Medical Center
    Omaha, Nebraska

    Disclosures

    Matthew Lunning, DO, FACP, has the following relevant financial relationships:
    Consultant or advisor for: AbbVie; ACROTECH; ADC Therapeutics; Astellas; AstraZeneca; Bristol Myers Squibb; Daiichi Sankyo; Fate Therapeutics; Genentech; Genmab; Kite; Kyowa Kieron; Legend; MorphoSys; Novartis; Seagen Inc., formerly Seattle Genetics, Inc.; TG Therapeutics
    Research funding from: Bristol Myers Squibb; CURIS

Editor

  • Megan Whitney, DMD

    Medical Education Director, Medscape, LLC 

    Disclosures

    Megan Whitney, DMD, has no relevant financial relationships. 

Compliance Reviewer/Nurse Planner

  • Leigh Schmidt, MSN, RN, CNE, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements

This program has been developed through the strategic partnership between the University of Nebraska Medical Center and Medscape Oncology.



In support of improving patient care, University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • The University of Nebraska Medical Center designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Contact This Provider

    For Nurses

  • The University of Nebraska Medical Center designates this activity for up to 0.50 contact hours. Nurses should only claim credit for the actual time spent participating in the activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / CE

Case Challenges in Chronic Lymphocytic Leukemia

Authors: Matthew Lunning, DO, FACPFaculty and Disclosures

CME / CE Released: 8/31/2022

Valid for credit through: 8/31/2023

processing....

Educational Impact Challenge

The goal of this activity is that learners will be better able to obtain practical strategies to personalize treatment and manage side effects for patients with treatment-naive or relapsed/refractory (R/R) CLL.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.